Мукормикоз у онкогематологических больныгх в Санкт-Петербурге

Обследовано 36 больных мукормикозом в 10 стационарах Санкт-Петербурга с 2004 по 2013 гг. Наиболее частыми фоновыми заболеваниями мукормикоза были острые лейкозы (64%). Почти в 100% случаев у таких больных инвазивный мукормикоз развивается как внутрибольничная инфекция. Проанализированы факторы риска, этиологию, основные клинические признаки, особенности тактики лечения мукормикоза у гематологических больнык в Санкт-Петербурге.

гемабластозы, мукормикоз, антифунгальная терапия

1. Климко H.Н. Микозы: диагностика и лечение. Руководство для врачей 2-е издание.М.: 2008; 335.

2. Хостелиди С.Н. Главное о зигомикозе (обзор). Проблем мед. микол. 2006; 8: 4: 8-18.

3. Roden M.M., Zaoutis T.E., Buchanan W.L. et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.

4. De Pauw B., Walsh T.J., Donnelly J.P. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases. Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 12: 1813-1821.

5. Segal В.H., Herbrecht R., Stevens D.A. at al. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. CID 2008; 47: 674-683.

6. Skiada A., Pagano L., Groll A. et al. European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 12: 1859-1867.

7. Pagano L., Valentini C.G., Posteraro B. et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). Chemotherapy 2009; 3: 322-329.

8. Petrikkos G., Skiada A., Lortholary O., Roilides E., Walsh T.J., Kontoyiannis D. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54: 1: 23-34.

9. Pagano L., Fianchi L., Leone G. Fungal pneumonia due to molds in patients with hematological malignancies. Chemotherapy 2006; 18: 4: 339-352.

10. Pagano L., Offidani M., Fianchi L. et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 2: 207-214.

11. Lanternier F., Dannaoui E., Morizot G., Elie C., Garcia-Hermoso D., Huerre M., Bitar D., Dromer F., Lortholary O., French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54: 1: 35-43.

12. Gleissner B., Schilling A., Anagnostopolous I., Siehl I., Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004; 45: 7 1351-1360.

13. Javier Pastor F., Guarro J. Micafungin: experimental therapy of fungal infections in animal models. Rev Iberoam Micol 2009; 26: 1: 42-48.

14. Ogawa T., Takezawa K., Tojima I., Shibayama M., Kouzaki H., Ishida M., Okabe H., Shimizu T. Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin. Auris Nasus Larynx 2012; 39: 2: 224-228.

15. Van Sickels N., Hoffman J., Stuke L., Kempe K. Survival of a patient with trauma-induced mucormycosis using an aggressive surgical and medical approach. J Trauma 2011; 70: 2: 507-509.

16. Khostelidi S.N., Klimko N.N., Bogomolova T.S. et al. Mucormycosis in Saint Petersburg, Russia. Mycosеs: Diagn, Ther Prophyl of Fungal Dis 2011; 54: 2: 99.

17. Khostelidi S.N., Klimko N.N., Bogomolova T.S. et al. Mucormycosis in patients with haematological and oncologycal diseases in Saint-Petersburg, Russia. 22nd European Congress of Clinical Microbiology and Infectious Diseases. Book of abstracts. London, United Kingdom. 2012; 162.